MAP Kinase Kinase Kinase 3
"MAP Kinase Kinase Kinase 3" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A 70-kDa MAPK kinase kinase with specificity for MAP KINASE KINASE 5.
| Descriptor ID |
D048748
|
| MeSH Number(s) |
D08.811.913.696.620.682.700.559.300 D12.644.360.400.300 D12.776.476.400.300
|
| Concept/Terms |
MAP Kinase Kinase Kinase 3- MAP Kinase Kinase Kinase 3
- MAPK-ERK Kinase Kinase 3
- MAPK ERK Kinase Kinase 3
- MEK Kinase 3
- MEKK3 Protein Kinase
- Protein Kinase, MEKK3
- Mitogen-Activated Protein Kinase Kinase Kinase 3
- Mitogen Activated Protein Kinase Kinase Kinase 3
- MAP3K3 Protein Kinase
- Protein Kinase, MAP3K3
- ERK Kinase Kinase 3
|
Below are MeSH descriptors whose meaning is more general than "MAP Kinase Kinase Kinase 3".
Below are MeSH descriptors whose meaning is more specific than "MAP Kinase Kinase Kinase 3".
This graph shows the total number of publications written about "MAP Kinase Kinase Kinase 3" by people in this website by year, and whether "MAP Kinase Kinase Kinase 3" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2016 | 1 | 0 | 1 |
| 2020 | 0 | 2 | 2 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "MAP Kinase Kinase Kinase 3" by people in Profiles.
-
PIK3CA and CCM mutations fuel cavernomas through a cancer-like mechanism. Nature. 2021 06; 594(7862):271-276.
-
Cerebral Cavernous Malformation Proteins in Barrier Maintenance and Regulation. Int J Mol Sci. 2020 Jan 20; 21(2).
-
Symptomatic Brain Hemorrhages from Cavernous Angioma After Botulinum Toxin Injections, a Role of TLR/MEKK3 Mechanism? Case Report and Review of the Literature. World Neurosurg. 2020 Apr; 136:7-11.
-
Cerebral cavernous malformations arise from endothelial gain of MEKK3-KLF2/4 signalling. Nature. 2016 Apr 07; 532(7597):122-6.
-
The biology and clinical development of MEK inhibitors for cancer. Drugs. 2014 Dec; 74(18):2111-28.